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Abstract: B a c k g r o u n d :  Regulation of energy balance in patients with short bowel syndrome (SBS) is 
disturbed due to lack of significant part of the intestine. The goal of the research was to analyse the plasma 
concentrations of selected regulatory peptides — ghrelin, visfatin, and irisin — in children with SBS. 
M eth o d s: To achieve this aim we recruited study group consisted of 28 children with SBS fed parenterally 
for at least two weeks, mean age 14 ± 5 months and mean standardised body mass index (SDS-BMI) 
-1 .26 ± 0.84. The control group was represented 25 healthy children of matching age and SDS-BMI. The 
plasma concentrations of peptides (ghrelin, visfatin, and irisin) were determined using immunoassays, 
and liver enzymes (AST, ALT, GGT) using an auto-analyser.
R e s u l t s :  We observed lower visfatin and ghrelin levels in the study group as compared to controls 
(both P <0.0001). The lowest total ghrelin concentration was observed in SBS children after ileal resection 
(P = 0.0016). Irisin concentration did not differ between the groups. Most o f the SBS children showed 
elevated liver enzymes activities at the first measurement and during one-year follow-up. 
C o n c l u s i o n :  Our findings showed that plasma ghrelin and visfatin themselves may play a role in the 
course of SBS, while a lack of disturbance in irisin might imply that it is neither playing any role nor it 
is affected by SBS itself.
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Introduction
Short Bowel Syndrome (SBS) is a life-threatening condition with high mortality 
and morbidity [1]. The SBS prevalence depends much on the maturity of children/ 
newborns. Despite the overall incidence of SBS of 1200/100,000 live births, the 
mortality rate is very high. Reported survival rates in paediatric SBS range from 73% 
to 89%, making it one of the most lethal conditions in infancy and childhood [2, 3]. 
A multidisciplinary treatment program has been associated with better survival; 
however, it is very expensive [1, 2]. Patient outcome depends mainly on the length of 
resected (or remaining) bowel, which influences directly the degree of malabsorption, 
and in consequence the need for specialised enteral or parenteral nutrition (PN) [3]. 
An increasing number of patients require long-term PN, which is accompanied by 
the risk of developing serious complications such as parenteral nutrition-associated 
liver disease (PNALD). PNALD is the most common cause of death for patients 
suffering from SBS [4-6]. Partial resection of intestine has an influence on the many 
gastrointestinal hormones [7]. It is known that disturbed gut-brain axis is one of 
the reasons of malnutrition in such patients [8, 9]. One of the representatives of 
gastrointestinal peptides is ghrelin — a physiological hunger-signal initiator, which 
is secreted primarily by the oxyntic mucosa of the gastric fundus [10]. Ghrelin serves 
multiple functions contributing to intestinal adaptation after massive small bowel 
resection [10-12]. On the other hand, ghrelin may induce a negative energy balance 
by decreasing food intake and delaying gastric emptying [10, 13]. Structural and 
physiological alterations in patients with SBS also generate secondary disturbances 
in the secretion of regulatory peptides from distal parts of the gut and even from 
other tissues, such as adipose tissue [3]. Variances in the post-resection release of 
gastrointestinal regulatory peptides may cause secondary adipokine or myokine 
secretion disturbances, which may also play an important role in the regulation of 
liver function and intestinal adaptation. Visfatin, a novel anti-inflammatory adipokine, 
produced primarily by visceral and subcutaneous fat and hepatocytes, is involved in 
multiple biological functions, including glucose and lipid metabolism, and energy 
homeostasis [14, 15]. Some authors have linked visfatin with the pathogenesis of liver 
cirrhosis and disease progression [16]. Monitoring of this parameter could be useful 
and easily obtainable marker of PNALD. Recently described is irisin, a molecule 
secreted from skeletal muscle, involved in transforming white adipose tissue to brown 
adipose tissue and in increasing energy expenditure [17]. Irisin improves glucose 
homeostasis and lipid metabolism [18]. An elevated concentration of this molecule 
is observed in obese patients, and may therefore be used as a potential biomarker of 
energy balance [19].
The aim of this study was to analyse the plasma concentrations of ghrelin, 
visfatin and irisin in children with SBS in relation to the postsurgical anatomy of the
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gastrointestinal tract. Our findings may help to discover new biomarkers for early 
detection of SBS children at risk and significantly improve the quality of life and limit 
mortality in this group.
Materials and Methods
Participants
We recruited 28 consecutive infants with a clinical diagnosis of SBS to a prospective 
cohort study. SBS was defined as loss of at least 50% of the small intestinal length from 
surgical resection or congenital defect. The study was limited to patients <6 weeks of 
age at the time of SBS onset, totally parenterally fed for at least two weeks. Detailed 
clinical data are presented in Table 1. Patients were excluded from the trial if they had 
a termination of PN, other feeding protocols, or systemic or severe chronic disease 
(besides SBS). All nutrition requirement was covered by PN and the prescription 
followed a standard protocol. Amino acids were given in the amount to cover daily 
requirements. Per 1 g of amino acid nitrogen, 175 other calories were administered 
in the proportions of 70% carbohydrates to 30% lipids. The control group recruited in 
a day-care centre was represented by 25 healthy infants (Table 1). These infants (36% 
girls) were breastfed or fed with regular age-appropriate formula. In all individuals, we 
evaluated standardised body mass index (SDS-BMI) after adjustment for gestational 
age and gender.
Table 1. Demographic and Clinical Data.
Variable SBS children (n = 28) Control (n = 25)
age, months 14 ± 5 16 ± 7
female, % 9 (32) 9 (36)
SDS-BM I, kg/m2* -1 .26 ± 0.84 -0 .81 ± 0.55
TPN time, days 22 (17-31)
last surgery, days 24 (16-34)
cause of SBS
necrotizing enterocolitis, % 9 (32)
gastroschisis, % 5 (18)
intestinal atresia, % 5 (18)
meconium ileus, % 5 (18)
cystic fibrosis, % 2 (7)
other, % 2 (7)
8
Table 1. Cont.
Variable SBS children (n = 28) Control (n = 25)
part of resected bowel
jejunum resection, % 5 (18)
jejuno-ileum resection, % 4 (14)
ileum resection, % 9 (32)
jejunocolic resection, % 0
ileocolic resection, % 2 (7)
colon resection, % 6 (22)
jejuno-ileum and colon resection, % 2 (7)
cause of SBS in isolated ileum resection subgroup
necrotizing enterocolitis, % 4 (45)
gastroschisis, % 1 (11)
intestinal atresia, % 2 (22)
meconium ileus, % 2 (22)
Continuous variables are presented as a median (interquartile range) or a mean ± standard deviation and 
categorical variables are presented as numbers (percentages).
Abbreviations: SDS-BMI, body mass index sd score; SBS, short bowel syndrome.
^ e  protocol of the study was approved by the Jagiellonian University Bioethical 
Committee (opinion no. 122.6120.154.2015). All subjects’ parents or legal guardians 
provided written informed consent prior to inclusion in the study.
Assays
All infants underwent a venipuncture in the morning, before feeding. Plasma was 
separated by centrifugation and stored in 200 ^l aliquots at -80°C  until further 
analysis. Plasma concentrations of total ghrelin were measured using commercial 
sandwich enzyme-linked immunosorbent assay (ELISA) kits supplied by Merck 
Millipore (Darmstadt, Germany). For the quantitative determination of visfatin and 
irisin, we used the commercial ELISA kit from BioVendor (Brno, Czech Republic). 
^ e  measurements were conducted according to the manufacturers’ guidelines. We 
also measured the activity of liver enzymes: serum aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) using
Julita Pabisek-Miernik, Barbara Koscielniak-M erak, et al.
Ghrelin, visfatin and irisin in children with short bowel syndrome
a VITROS 5.1 auto-analyser (Ortho Clinical Diagnostics, USA) during one-year 
follow-up.
Statistical analysis
Categorical variables were presented as counts and percentages; continuous variables 
were expressed as a mean ±  standard deviation or as a median and interquartile range 
(IQR). Normality was assessed by the Shapiro-Wilk test in each group. The differences 
between the groups were compared by the Student’s t-test for normal distribution 
variables or U-Mann-Whitney test for continuous variables with a distribution 
different from normal. A probability of <0.05 was considered statistically significant. 




Clinical and demographic data of studied and control groups are presented in Table 1. 
We observed lower total ghrelin and visfatin concentrations in the study group when 
compared to control individuals (97.78 ± 19.65 pg/ml vs. 182.17 ± 65.44 pg/ml; 
P <0.0001, and 1.05 ± 0.96 ng/ml vs. 6.42 ± 3.27 ng/ml; P <0.0001 respectively, 
Fig. 1A and 1B). We found that children after isolated ileum resection (32%) had 
significantly lower total ghrelin concentration when compared to the other SBS 
children (69.28 pg/ml ± 17.05 vs. 126.99 ± 24.57 pg/ml; P = 0.006). We did not 
find any differences in the irisin concentration between healthy and SBS children 
(2.67 ± 0.72 mg/l vs. 2.76 ± 1.41 mg/l; P = 0.69, Fig. 1C). At the first measurement 
in the study an elevated activity of ALT was observed in 84% of patients (mean 
multiplicity of the upper limit of reference range was 2.1 ± 0.9) and during one year 
we did not note any significant changes. AST activity during initial determination was 
increased in 56% of the study group (mean multiplicity of the upper limit of reference 
range was 1.7 ± 0.2) and did not change significantly during the study time. Elevated 
activity of GGT was found in 76% of SBS patients (mean multiplicity of the upper 
limit of reference range was 2.9 ± 0.7) with no significant alterations during one-year 
follow-up. We also observed a negative correlation between visfatin concentration and 
ALT activity in the SBS children at the first measurement (P = 0.0012; R = -0.41). No 
correlations between ghrelin or irisin with liver enzyme activity were found at all time 
points.
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Fig. 1. Difference between the ghrelin, visfatin and irisin concentration between control and SBS 
patients. A. Mean active ghrelin concentration in the study (n = 28) and control group (n = 25). B. Mean 
concentration of visfatin in the study and control group. C. Mean concentration of irisin in the study 
group and control group. Middle point = mean value; box = standard error of the mean; bars = standard 
deviation.
Discussion
To our knowledge, this study is the first to demonstrate a decrease in plasma ghrelin 
and visfatin concentrations in children suffering from SBS treated with PN. This area 
of research is important as SBS is a life-threatening condition.
Ghrelin has a vast range of physiological functions, including orexigenic, 
metabolic and hormonal functions [10]. The data about levels of this peptide plasma 
after partial resection of the gut are contradictory. In animal studies, it was indicated
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that ghrelin secretion in the stomach increases immediately after massive small- 
bowel resection. It was concluded to be a compensation mechanism protecting 
from malnutrition [20]. ^ i s  observation was confirmed in the clinical study in 
nine adult SBS patients with jejuno-colonic anastomosis [20]. On the other hand, 
Krsek et al. observed a lower concentration of ghrelin in 24 SBS patients when 
compared to healthy individuals [21]. Although the highest concentration of ghrelin 
is found in the stomach, the authors noted that a significant amount of ghrelin is 
likewise produced by intestinal neuroendocrine cells in the whole intestine [21]. 
The authors hypothesised that plasma ghrelin concentration decreases in SBS 
patients due to a massive resection of tissue mass that is able to secret ghrelin in 
substantial amounts [21]. It was justified by observations by Date et al., that ghrelin 
is also secreted by endocrine cells in the small intestine [22]. Similarly, in our study, 
ghrelin levels were diminished in SBS children as compared to healthy children. 
Lower ghrelin levels in paediatric SBS patients may result not only from the loss of 
intestinal neuroendocrine cells secreting ghrelin, but from disturbances in feedback 
regulation between different parts of the gut [7]. We found that children following 
exclusively ileal resection had significantly lower ghrelin concentration than did other 
SBS children. ^ i s  is surprising because Gillard et al. suggested that jejuno-colonic 
anastomosis creates a specific environment that increases hunger signals and may 
be associated with higher ghrelin secretion [20]. ^ i s  discrepancy could result from 
a different age of studied groups, and therefore differences in regulatory mechanisms. 
Recently, Yamada et al. have indicated that the administration of ghrelin diminishes 
PN-associated intestinal mucosal atrophy due to an increased villus height and crypt 
depth [12]. ^ e y  highlighted the clinical significance of ghrelin application, which 
is likely to show promise in the treatment of malnutrition, particularly in paediatric 
patients with SBS [12]. Monitoring of ghrelin concentration seems to be a marker of 
intestinal adaptation in paediatric SBS patients.
Visfatin is expressed at highest levels in adipose tissue, liver, muscles, and 
bone marrow [14, 15]. A recent study performed by de Boer et al. showed that 
concentration of plasma visfatin was significantly lower in cirrhotic patients (children 
and adults) compared to healthy controls [16]. ^ e y  also noted that visfatin levels 
decreased together with the worsening stage of disease [16]. ^ e  authors hypothesised 
that the main reason for the reduction of circulating visfatin levels in those patients is 
decreased hepatic synthetic function as a result of hepatocyte damage [16]. Similarly, 
conclusions were reported by Kukla et al. who evaluated visfatin expression in liver 
biopsy samples using immunohistochemical assay [23]. ^ e  authors described the 
negative association between circulating visfatin concentrations and the fibrosis stage 
in non-alcoholic fatty liver disease (NAFLD) and suggested a potential role of this 
molecule in the pathogenesis of NAFLD [22]. In our study, visfatin levels were lower 
in SBS patients compared to the healthy subjects and negatively correlated with serum
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ALT activity. These observations suggest that diminished concentration of plasma 
visfatin could be recognised as a predictive factor of PN-associated liver fibrosis. 
In our samples, the elevated activity of liver enzymes was detected and therefore 
suggested early/minor liver disease of SBS children. The clinical utility of visfatin as 
a marker of PNALD requires further elucidation.
Irisin is a recently identified novel myokine [17]. Some authors reported increased 
irisin concentration in obese patients, and its reduction after weight loss [24, 25]. 
Moreover, Crujeiras et al. observed that irisin concentration increased when weight 
loss was reversed [24]. On the other hand, Sanchis-Gomar et al. reported lack of 
correlation between irisin level and BMI [26]. These contrasting observations could 
be the results of the measurement differences because there is still no consensus 
concerning the identification of the circulating, soluble irisin molecules, the varying 
presence of target epitopes among manufacturers, and finally differing mechanisms 
of secretion [27, 28]. In spite of the existing controversy, most authors indicated 
correlations between irisin and different markers of adiposity, suggesting that plasma 
irisin levels reflect body adiposity. Recently the associations between irisin and 
liver diseases have been shown [27-29]. Choi et al. noted higher levels of irisin in 
patients with NAFLD, suggesting a potential role of irisin in the pathogenesis of 
this disease [29]. Furthermore, Rizk et al. found increased irisin levels in metabolic 
syndrome patients with elevated levels of liver enzymes [28]. They indicated 
a relationship between circulating irisin concentration and lipid as well as glucose 
metabolism [28]. However, in our study, we did not observe any changes in this 
peptide concentration in SBS children. Primarily, the lack of the alterations in irisin 
concentrations could be due to the similarity between the study and control groups 
according to SDS-BMI, which may exclude the possible variances in the secretion of 
the analysed peptides depending on differences in adipose and muscle tissue volume. 
Secondly, it may suggest no functional connection between gut peptides and the 
peptides secreted from skeletal muscles.
Study limitations
The limitation of the study lies in the small number of members of the study 
groups. However, SBS children with TPN are a unique group, and 25 patients 
could be recognised as a sufficient sample size. It is a consequence of the rarity of 
SBS and underlying pathology. However, due to statistical rules, this may lead to 
underestimation of the possible association between variables (type II error). This and 
other possible similar limitations could be overcome by increasing the sample size, 
thus improving the statistical power of the study.
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Conclusion
Our research indicates that energy misbalance in children with SBS is associated with 
secretion of peptides from the gastrointestinal tract as well as with the secretion of 
peptides from adipose tissue and liver, while myokines pathways are not disturbed.
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